Top

News & Events

Xellia Pharmaceuticals Welcomes HM the Queen of Denmark to Zagreb R&D Center of Excellence During State Visit to Croatia

Xellia Pharmaceuticals Welcomes HM the Queen of Denmark to Zagreb R&D Center of Excellence During State Visit to Croatia

Xellia is one of only three Danish companies visited during four day National tour

Copenhagen, Denmark and Zagreb, Croatia – 23 October 2014 – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announced that HM the Queen Margrethe II of Denmark visited the Company’s Product and Innovation R&D Center of Excellence in Zagreb on Wednesday 22 October during her State visit to Croatia.

Xellia is one of only three Danish companies that the Queen and HRH the Prince Consort visited during the four day tour of Croatia and the only one where the Royal Couple were accompanied by the Danish Minister for Food, Agriculture and Fisheries.

For Minister Mr. Dan Jørgensen antimicrobial resistance, in particular the One Health initiative which unites human and veterinary medicine to reduce the use of unnecessary antibiotics has been a priority since his election in December 2013.

Carl-Åke Carlsson, CEO Xellia said: “It is a great honour to be able to welcome HM the Queen, HRH the Prince Consort and Minister for Food, Agriculture and Fisheries to Xellia during this State visit to Croatia. Being one of only three companies selected for the visit is a great compliment to the management and staff at Xellia.

“Our company has expanded rapidly over the past 12 months including an investment of US$2 million in the Zagreb R&D Center of Excellence and the opening of our first facility in the US. This positions us well to achieve our ambitious plans for growth.”

During a tour of the site the Royal Couple and the Minister discussed the important role Xellia has played in the battle against infectious diseases and Xellia’s heritage in the development, manufacture and supply of anti-microbial products to over 500 pharmaceutical customers. The Company’s important work to help tackle the global crisis of antimicrobial resistance was also a key focus; every year more than 25,000 European citizens die from infections caused by bacteria that have developed resistance towards antimicrobials.

Dr Aleksandar Danilovski, Vice President Global R&D and Managing Director of the Zagreb site said, “The R&D Center of Excellence in Zagreb plays a vital role in our global strategy of innovation and product development. We are dedicated to developing improved and novel anti-infective products that combat serious life-threatening bacterial and fungal infections.

“Our focus is on multi-drug resistant bacteria and fungi with the aim of preserving the power of existing anti-infective treatments as well as helping to create new ones. It was a great opportunity to be able to show the Royal Couple and the Minister the valuable work we do at Xellia.”

 

Notes for Editors

About Xellia

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, USA, Hungary and China, and currently employs over 1,000 people.

Xellia is a leading supplier of vancomycin and colistimethate sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen), supported by a grant from the Research Council of Norway.

Since July 2013, Xellia has been wholly owned by Novo A/S, the holding Company of the Novo Group.

Further information about Xellia can be found at: www.xellia.com.

 

Issued for and on behalf of Xellia by Instinctif Partners.

To contact the Xellia team at Instinctif Partners, email xellia@instinctif.com

back to news

People

Melanie Toyne-SewellManaging Partner